Atezolizumab biosimilar is an Fc-engineered, humanized, monoclonal antibody that binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors. Atezolizumab biosimilar is a non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa.
Atezolizumab biosimilar is supplied at a concentration of 60 mg/mL as a sterile, preservative-free, colorless to slightly yellow solution, which contains 16.5 mg/ mL glacial acetic acid, 62 mg/mL L-histidine, 821.6 mg/mL sucrose, 8 mg/mL polysorbate 20, pH 5.8.
Statement: this product is used for R&D only, not for clinical usage.
|
Name
|
Atezolizumab biosimilar
|
|
CAS NO.
|
1380723-44-3
|
|
Type
|
Whole antibody
|
|
Source
|
Humanized
|
|
Target
|
PD-L1
|
|
Clone
|
Monoclone
|
|
Molecular Weight
|
145 kDa
|
|
Formula
|
C6446H9902N1706O1998S42
|
|
Antibody Form
|
Purified immunoglobulin
|
|
Physical Form
|
Solution
|
|
Grade Standard
|
Medicine Grade
|
|
Place of Origin
|
China(Mainland)
|
|
Storage
|
-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
|
bio-equip.cn
Shanghai Topwell Pharma Co., Ltd. is specialized in research, development, custom manufacturing and sales of Pharmaceutical Intermediates, APIs, Pharmaceutical Excipients, Health & Nutritional Ingredients, Polypeptides and Antibodies, etc..
Topwell has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories.
Topwell aims to become a global leader in pharmaceutical & chemical industry.
中文
